Positive results reported in HER2 mutated lung cancer
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
Search
First Patient Enrolled in New Cardiovascular and Renal Outcomes Trial for TRADJENTA® (linagliptin) Tablets in Type 2 Diabetes
First Patient Enrolled in New Cardiovascular and Renal Outcomes Trial for TRADJENTA® (linagliptin) Tablets in Type 2 Diabetes
Lars Dreesmann Named President of Boehringer Ingelheim Fremont, Inc.
Lars Dreesmann Named President of Boehringer Ingelheim Fremont, Inc.
FDA Grants Fast Track to Jardiance® (empagliflozin) for CKD | Boehringer Ingelheim US
The FDA has granted Fast Track designation for JARDIANCE to reduce risk of disease progression and CV death with CKD. View ISI, PI & Med Guide.
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
Medicines reach record number of people, net sales rise
Championing minds for generations both in and out of the workplace
Boehringer Ingelheim is now certified for Mental Health America’s (MHA) Bell Seal for Workplace Mental Health.
FIBRONEER™ trials for IPF, other progressive fibrosing ILDs
Donald Zoz, M.D., Director and Senior Clinical Program Leader for Pulmonary Fibrosis, discusses the FIBRONEER™ global clinical program
Phase III EMPA-KIDNEY trial will stop early
The EMPA-KIDNEY trial, evaluating the effect of Jardiance (empagliflozin) tablets in adults with chronic kidney disease (CKD), will stop early based on a recommendation from the trial’s Independent Data Monitoring Committee.
Results announced from EMPACT-MI phase III trial
Results announced from EMPACT-MI phase III trial in adults following a heart attack.
Sanofi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017
Sanofi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017
Linagliptin Demonstrated Significant HbA1c Reduction in Elderly People With Type 2 Diabetes With Inadequate Glycemic Control
Linagliptin Demonstrated Significant HbA1c Reduction in Elderly People With Type 2 Diabetes With Inadequate Glycemic Control
Recognizing Parents Supporting Other Parents
Recognizing Parents Supporting Other Parents
BI Presents Combination Data of Tiotropium + Olodaterol | Boehringer Ingelheim US
BI presented the first data from the pivotal Phase III TONADO™ 1&2 studies for the FDC of tiotropium plus olodaterol delivered via the Respimat® inhaler.
A future without pills – could AI change the way we treat psychiatric diseases?
Dr Cornelia Dorner-Ciossek talks about how her work with smartphone tech could transform how we treat mental illness.
Data Shows Jardiance® (empagliflozin) Cardiorenal Risk Reductions | Boehringer Ingelheim US
The EMPA-REG OUTCOME® trial shows JARDIANCE reduces CV and renal risk in adults with T2D & known CV disease. View ISI, PI & Med Guide.
FDA Approves OFEV® (nintedanib) to Treat IPF | BI US
Read more about the FDA approval of Boehringer Ingelheim's OFEV, the first Kinase Inhibitor used to treat idiopathic pulmonary fibrosis (IPF).
OFEV® (nintedanib) Now Available in the United States
OFEV® (nintedanib) Now Available in the United States
Ingelheim
The company headquarters of Boehringer Ingelheim are located in Ingelheim, Germany.
1885-1948: Innovative Beginnings | Boehringer Ingelheim US
Click here to read an in-depth history of Boehringer Ingelheim's formation, early days and what led us to being the global pharmaceutical company of today.
FDA Advisory Committee Recommends Approval of Tiotropium Respimat® for the Maintenance Treatment of COPD
FDA Advisory Committee Recommends Approval of Tiotropium Respimat® for the Maintenance Treatment of COPD
Intensive education about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines
The findings demonstrate the benefit of clinic-level educational interventions
FDA approves Ofev® as the first and only therapy to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD
FDA approves Ofev® as the first and only therapy to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD
Cyltezo® (adalimumab-adbm) Patent Litigation Resolution| BI US
Read more about Boehringer Ingelheim's CYLTEZO patent litigation resolution, meaning greater access to the treatment for patients across the USA.
New effort to help improve C-R-M health outcomes
Boehringer Ingelheim sponsors American Heart Association's Cardiovascular Kidney Metabolic Health Intiative (CKMH)
Standing together in support of improved access to obesity care
Learn more about how we’re supporting The Obesity Society and their recent consensus statement on obesity to help raise awareness and improve access to care for people living with this chronic medical condition.